Microbiome Connect: Europe, 6th-7th July
The 8th Annual Microbiome Connect: Europe 2022 is dedicated to showcasing the leading drug development and consumer product platforms applying live microbial consortia, engineered microbes, and microbial-derived metabolites for therapeutic and health applications in patients and consumers.
The microbiome field is making vast breakthroughs within R&D, manufacturing, and consumer product platforms by applying live microbial consortia, engineered microbes, and microbial-derives metabolites for therapeutic and health applications in patients and consumers worldwide.
The event will take place face-to-face, on July 6-7 in Amsterdam.
As the first EMA approved microbiome-targeted therapeutics emerge on the horizon, this is a prime opportunity for academia, pharma, biotech and service providers to network in-person to share the latest clinical data and benchmark their rational drug platforms, targeting validated pathways in gastrointestinal, neurological, metabolic disorders, as well as oncology-based indications.
Join 50+ industry leaders including:
- Staffan Stromberg, CEO, Infant Bacterial Therapeutics
- Todd Krueger, CEO, AOBiome
- Jean-Luc Marsat, CEO, Everimmune
- Isabelle de Cremoux, CEO, Seventure
- Robert Jan Brummer, Pro-Vice-Chancellor, Örebro University
Visit the Kisaco Research website to view the full event schedule and to register.
Use the code N8ICIO to get 10% off your ticket.